IgG aCL were found to have a significant association with thrombosis and thrombocytopenia, and IgM aCL with haemolytic anaemia and neutropenia. Specificity and predictive value for these clinical manifestations increased at moderate and high anticardiolipin antibody titres. In addition, a significant association was found between aCL and the presence of lupus anticoagulant. Identification of these differences in the anticardiolipin antibody isotype associations may improve the clinical usefulness of these tests, and this study confirms the good specificity and predictive value of the anticardiolipin antibody titre for these clinical manifestations.
Several recent studies found that patients with antiphospholipid antibodies (aPL) are prone to repeated episodes of venous or arterial thrombosis, or both,1-11 recurrent fetal loss,8 [11] [12] [13] [14] [15] and thrombocytopenia.26 8 9 11 15 6In addition, there have been reports of the possible association of aPL with haemolytic anaemia'7 and neurological events such as cerebrovascular 18 1920 accidents, seizures, migraine,'9 and chorea.
Other authors, however, consider that no association exists and aPL are only an epiphenomenon. [21] [22] [23] In fact, few prospective studies of a large number of unselected patients have been carried out and no definitive conclusions have been reached.
Of the various aPL, anticardiolipin antibodies (aCL) have received more attention owing to their sensitive, reproducible, and reliable detection by radioimmunoassay3 or enzyme linked immunosorbent assay (ELISA). 24 Several studies suggest that aCL are closely related to the lupus anticoagulant and the biological false positive standard tests for syphilis (BFP-STS).6 Although these antibodies are not restricted to patients with systemic lupus erythematosus (SLE), they are often found in these patients.
Our main objectives were to determine the prevalence of IgG and IgM anticardiolipin antibody isotypes in 100 16 variables previously described showed significant correlations with thrombosis (p=0 001) and thrombocytopenia (p=0 03), but not with SLE activity. Table 2 shows the sensitivity, specificity, and predictive value of the IgG anticardiolipin antibody test at low, moderate, and high anticardiolipin antibody titres for thrombosis and thrombocytopenia. At low titre the specificity of the IgG anticardiolipin antibody test for thrombosis and thrombocytopenia was greater than 80%, the sensitivity for thrombosis was 70% and for thrombocytopenia 47%, but the predictive values were quite low. At moderate and high titres, however, the specificity of the test for both thrombosis and thrombocytopenia varied from 89% to 96% and its predictive value was in 16 variables showed significant correlations with haemolytic anaemia (p=0-015) and neutropenia (p=001). Table 3 shows sensitivity, specificity, and predictive value of the IgM anticardiolipin antibody test at low, moderate, and high antibody titres for haemolytic anaemia and neutropenia. At moderate and high titres the specificity of the test for both variables exceeded 80%, the sensitivity for haemolytic anaemia was 44% and for neutropenia 60%. When the binding index was 11 the predictive value for haemolytic anaemia was 60%, and when the binding index was 3 15 the predictive value was 100%. In 
